Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis

Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis

Background. Treatment of hepatitis C virus (HCV) infection with newer direct-acting antivirals is unrealistic in some countries because of the lack of availability.Aim. Assess benefits and harms of boceprevir (BOC) and telaprevir (TLV) in treatment of genotype 1 HCV infection, and identifying subgro...

Full description

Bibliographic Details
Main Authors: María del Carmen Manzano-Robleda, Victoria Ornelas-Arroyo, Tonatiuh Barrientos-Gutiérrez, Nahum Méndez-Sánchez, Misael Uribe, Norberto C. Chávez-Tapia, M.D.
Format: Article
Language:English
Published: Elsevier 2015-01-01
Series:Annals of Hepatology
Subjects:
Direct acting antiviral
Sustained virological response
Protease inhibitor
Adverse drug event
Evidence based medicine
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119308002

Internet

http://www.sciencedirect.com/science/article/pii/S1665268119308002

Similar Items